Scholar Rock Holding (SRRK) Shares Outstanding (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Shares Outstanding (Entity) of $119.1 million for Q1 2026, up 25.54% year-over-year from $94.9 million in Q1 2025, and up 9.81% quarter-over-quarter from $108.5 million in Q4 2025.
Scholar Rock Holding (SRRK) Shares Outstanding (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $119.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 25.54% year-over-year to $119.1 million; the TTM figure through Mar 2026 stood at $119.1 million (up 25.54% YoY), while the FY2025 annual figure was $108.5 million, up 15.6% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $119.1 million, up from $108.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $119.1 million in Q1 2026, with the low at $35.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $80.1 million (2024), against an average of $80.9 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) soared 129.3% in 2022, then slipped 0.65% in 2024.
- Scholar Rock Holding's Shares Outstanding (Entity) stood at $51.7 million in 2022, then soared by 47.04% to $76.0 million in 2023, then increased by 23.49% to $93.8 million in 2024, then rose by 15.6% to $108.5 million in 2025, then gained by 9.81% to $119.1 million in 2026.
- Business Quant data shows SRRK's Shares Outstanding (Entity) at $119.1 million in Q1 2026, $108.5 million in Q4 2025, and $99.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 130.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.61 Mn |
| Mar 31, 2026 | 127.28 Mn |
| Dec 31, 2025 | 114.70 Mn |
| Sep 30, 2025 | 113.73 Mn |
| Jun 30, 2025 | 112.70 Mn |
| Mar 31, 2025 | 111.84 Mn |
| Dec 31, 2024 | 99.84 Mn |
| Sep 30, 2024 | 97.05 Mn |
| Jun 30, 2024 | 96.81 Mn |
| Mar 31, 2024 | 95.89 Mn |
| Dec 31, 2023 | 83.35 Mn |
| Sep 30, 2023 | 80.61 Mn |
| Jun 30, 2023 | 80.12 Mn |
| Mar 31, 2023 | 79.61 Mn |
| Dec 31, 2022 | 59.61 Mn |
| Sep 30, 2022 | 79.34 Mn |
| Jun 30, 2022 | 41.62 Mn |
| Mar 31, 2022 | 37.46 Mn |
| Dec 31, 2021 | 36.71 Mn |
| Sep 30, 2021 | 36.68 Mn |